Childhood cancer clinical trials endangered by possible budget slashes

0 Views
Published
WASHINGTON (SOA) — It wasn't that long ago that childhood leukemia was essentially a death sentence. Today, the vast majority of kids survive, thanks in large part to federally funded clinical trials, many of which could be in jeopardy if their already dwindling budget sustains further cuts.

Read more: https://thenationaldesk.com/news/spotlight-on-america/childhood-cancer-clinical-trials-endangered-by-possible-budget-slashes-cog-leukemia-oncology

#ChildhoodCancer #CancerResearch #ClinicalTrials #PediatricOncology #LeukemiaAwareness #COG #SaveCancerFunding #SpotlightOnAmerica #HealthcareCrisis #CancerFunding #ResearchMatters #ProtectKidsHealth #OncologyResearch #BudgetCuts #MedicalBreakthroughs

_______________
Follow KFDM on social media:

KFDM on Facebook: https://www.facebook.com/KFDMNews/
KFDM on Twitter: https://twitter.com/kfdmnews

Subscribe to KFDM on YouTube: https://www.youtube.com/@newsonkfdm/featured


For all of the day’s top local and national news, visit https://kfdm.com/
Watch our live newscasts and other live video at https://kfdm.com/watch


Have a news tip? Send it directly to us:

Email us: [email protected]
Call the Newsroom: 409.892.6622


KFDM is a TX based station and CBS Television affiliate owned and operated by Sinclair Broadcast Group. KBTV is a TX based station and Fox Television affiliate owned and operated by Deerfield Media, Inc and receives certain services from an affiliation of Sinclair Broadcast Group. Sinclair, Inc. is one of the largest and most diversified television broadcasting companies in the country today. Sinclair owns and operates, programs or provides sales services to 163 television stations in 77 markets, after pending transactions. Sinclair's television group reaches approximately 38.7% of US television households and includes FOX, ABC, MyTV, CW, CBS, NBC, Univision and Azteca affiliates.

#kfdm #kfdmnews #beaumont #beaumontnews #KFDM #KFDMNews #localnews #breakingnews
Category
Oncology
Be the first to comment